Literature DB >> 23877678

Effect of pulmonary surfactant on antimicrobial activity in vitro.

R Schwameis1, Z Erdogan-Yildirim, M Manafi, M A Zeitlinger, S Strommer, R Sauermann.   

Abstract

Time-kill curve experiments were performed with linezolid, doripenem, tigecycline, moxifloxacin, and daptomycin against Staphylococcus aureus and with colistin, moxifloxacin, and doripenem against Pseudomonas aeruginosa to evaluate the effect of porcine pulmonary surfactant on antimicrobial activity. Pulmonary surfactant significantly impaired the activities of moxifloxacin and colistin. When antibiotics are being developed for respiratory tract infections, the method described here might be used to preliminarily quantify the effect of pulmonary surfactant on antimicrobial activity.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23877678      PMCID： PMC3811439          DOI： 10.1128/AAC.00778-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  J Li; J Turnidge; R Milne; R L Nation; K Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Lung preservation in experimental ischemia/reperfusion injury and lung transplantation: a comparison of natural and synthetic surfactants.

Authors:  Lars Knudsen; Laura Boxler; Christian Mühlfeld; Inga-Marie Schaefer; Laura Becker; Christine Bussinger; Immanuel von Stietencron; Navid Madershahian; Joachim Richter; Thorsten Wahlers; Thorsten Wittwer; Matthias Ochs
Journal:  J Heart Lung Transplant       Date:  2012-01       Impact factor: 10.247

3.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

4.  Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant.

Authors:  Dominique Dugourd; Haiyan Yang; Melissa Elliott; Raymond Siu; Jacob J Clement; Suzana K Straus; Robert E W Hancock; Evelina Rubinchik
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 5.  Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis.

Authors:  Neetu Singh; Kristy L Hawley; Kristin Viswanathan
Journal:  Pediatrics       Date:  2011-11-28       Impact factor: 7.124

6.  Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.

Authors:  Jared A Silverman; Lawrence I Mortin; Andrew D G Vanpraagh; Tongchuan Li; Jeff Alder
Journal:  J Infect Dis       Date:  2005-05-05       Impact factor: 5.226

7.  Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro.

Authors:  Robert Sauermann; Richard Schwameis; Manfred Fille; Maria Luciana Camuz Ligios; Markus Zeitlinger
Journal:  J Antimicrob Chemother       Date:  2009-07-21       Impact factor: 5.790

8.  Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.

Authors:  Mark H Gotfried; Jeng-Pyng Shaw; Bret M Benton; Kevin M Krause; Michael R Goldberg; Michael M Kitt; Steven L Barriere
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

9.  Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin.

Authors:  A van 't Veen; J W Mouton; D Gommers; J A Kluytmans; P Dekkers; B Lachmann
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Qin Lu; Rubin Luo; Liliane Bodin; Jianxin Yang; Noël Zahr; Alexandra Aubry; Jean-Louis Golmard; Jean-Jacques Rouby
Journal:  Anesthesiology       Date:  2012-12       Impact factor: 7.892
  10 in total
  19 in total

1.  Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Yang Hu; Nikolas J Onufrak; Siping Sun; Jiping Wang; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 2.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Mei-Ling Han; Ke Chen; Nikolas J Onufrak; Jiping Wang; John D Turnidge; Benjamin P Howden; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

4.  Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST).

Authors:  Jason M Pogue; Ronald N Jones; John S Bradley; David R Andes; Sujata M Bhavnani; George L Drusano; Michael N Dudley; Robert K Flamm; Keith A Rodvold; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

5.  Human Bile Reduces Antimicrobial Activity of Selected Antibiotics against Enterococcus faecalis and Escherichia coli In Vitro.

Authors:  Beatrix Wulkersdorfer; David Jaros; Sabine Eberl; Stefan Poschner; Walter Jäger; Enrico Cosentini; Markus Zeitlinger; Richard Schwameis
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.

Authors:  Yu-Wei Lin; Qi Zhou; Nikolas J Onufrak; Veronika Wirth; Ke Chen; Jiping Wang; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Soon-Ee Cheah; Jinxin Zhao; Ke Chen; Jiping Wang; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Mei-Ling Han; Nikolas J Onufrak; Ke Chen; Jiping Wang; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

9.  Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia.

Authors:  Brandon J H Banaschewski; Edwin J A Veldhuizen; Eleonora Keating; Henk P Haagsman; Yi Y Zuo; Cory M Yamashita; Ruud A W Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

10.  In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus.

Authors:  Tarani Kanta Barman; Manoj Kumar; Tarun Mathur; Eiko Namba; Diksha Singh; Tridib Chaira; Yuichi Kurosaka; Makiko Yamada; Dilip Jatashankar Upadhyay; Nobuhisa Masuda
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.